Related Experiment Video

Updated: Jul 19, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K

Ritlecitinib: First Approval

Hannah A Blair1

  • 1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|August 9, 2023
PubMed

Insights

Ritlecitinib, a new kinase inhibitor, is now approved in the US and Japan for severe alopecia areata. This oral medication offers a new treatment option for adults and adolescents with widespread hair loss.

Area of Science:

  • Pharmacology
  • Dermatology
  • Immunology

Background:

  • Alopecia areata is an autoimmune condition causing significant hair loss.
  • Current treatments for severe alopecia areata have limitations.
  • Ritlecitinib targets specific kinases involved in the autoimmune response.

Purpose of the Study:

  • To summarize the development milestones of ritlecitinib.
  • To highlight the regulatory approvals for alopecia areata treatment.
  • To provide an overview of ritlecitinib's journey to market.

Main Methods:

  • Review of clinical development data.
  • Analysis of regulatory submission timelines.
  • Summary of key efficacy and safety findings from trials (implied).

Main Results:

  • Ritlecitinib received US FDA approval on June 23, 2023, for severe alopecia areata in individuals 12 years and older.
  • Ritlecitinib gained Japanese approval on June 26, 2023, for intractable alopecia areata with widespread hair loss.
  • Positive opinion received in the EU, with ongoing reviews in the UK and China.

Conclusions:

  • Ritlecitinib represents a significant advancement in treating severe alopecia areata.
  • The drug's oral administration offers a convenient treatment option.
  • Successful regulatory approvals mark a major milestone in making this therapy available.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
204
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.1K